BPI Labs, LLC et al. v. Eli Lilly & Co.

IPR2025-01346

BPI Labs requests Director Review of the PTAB’s denial to institute an IPR against Eli Lilly’s tirzepatide patent (US 9,474,780). The petitioner argues the denial misapplies § 325(d), ignores material prosecution errors, and violates APA rulemaking requirements. Consistency with a related pending IPR is also urged.

Jurisdiction
US PTAB
Case Number
IPR2025-01346
Filing Date
8 April 2025
Status
ok

Related Cases

patentIPR2025-00431

Zhuhai CosMX Battery Co., Ltd.vsNingde Amperex Technology Ltd.

Zhuhai CosMX Battery challenges Ningde Amperex’s attempt to overturn a PTAB institution of a lithium‑battery patent, arguing the parallel‑petition issue is moot and the Board’s decision was proper and efficient.

patentIPR2025-01057

Ascentcare Dental Products, Inc.vsSolmetex, LLC

Ascentcare Dental Products has petitioned the PTAB to invalidate Solmetex’s 12,290,418 intraoral device patent, alleging obviousness over six prior‑art references. The petition seeks cancellation of 25 claims covering the isolation mouthpiece.

patentIPR2025-00658

Microsoft Corporation et al.vsDialect, LLC

Microsoft has filed an IPR petition challenging eight claims of Dialect’s 8,195,468 patent covering multimodal voice‑assistant technology, asserting obviousness over the Maes, Coffman, and Ittycheriah references. The petition argues the examiner never considered these references, creating a material error, and urges the Board to institute review.

patentIPR2025-00602

Amgen Inc. et al.vsBristol-Myers Squibb Company

The USPTO Director denied Amgen’s request for review of the institution decisions in IPR2025-00601 and IPR2025-00602, leaving the institution denials in place.

patentIPR2024-00634

Fluidmaster, Inc.vsDanco, Inc. et al.

Fluidmaster successfully moved forward with its IPR challenge against Danco's patent (9103105) regarding toilet fill valves. The Board granted institution on multiple grounds, setting the stage for a full trial to determine if the claims are unpatentable over prior art combinations.

Arctic Invent — IP Strategy

Dealing with a patent challenge?

Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.

Talk to our patent team →

Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.

Strategy Consult

Facing a similar patent matter?

Arctic's litigation team uses precedent data like this to build winning arguments.

Get a Strategy Call